Full text is available at the source.
Targeting the Gut-Brain Axis Through Insulin-like Growth Factors: Therapeutic Implications and Future Directions
Using Insulin-like Growth Factors to Influence the Gut-Brain Connection: Possible Treatments and Future Ideas
AI simplified
Abstract
Clinical evidence from 1989 to 2024 shows that gut microbiota-derived short-chain fatty acids may enhance IGF-1 production through novel molecular mechanisms.
- The gut-brain axis is a bidirectional communication network between the gastrointestinal tract and central nervous system.
- Insulin-like growth factors (IGFs), particularly IGF-1 and IGF-2, play essential roles in regulating intestinal barrier integrity and neurogenesis.
- There is a therapeutic interest in IGFs for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and depression.
- Current clinical trials on IGF-based therapies show preliminary promising results but are limited in scope and patient numbers.
- Key challenges in IGF-based treatments include safe delivery across biological barriers and variability in individual responses.
AI simplified